Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia / Schizoaffective Disorder, TMS
Efficacy and Safety of Individualized Sequential Accelerated Theta Burst Stimulation in Improving Cognitive Function in Schizophrenia
The goal of this clinical trial is to learn if sequential dual-site accelerated theta burst stimulation (SD-aTBS) targeting the frontoparietal network and default mode network works to improve cognitive function in adults with…
- Conditions
- Schizophrenia / Schizoaffective Disorder, TMS, Cognitive, PET / MR
- Trial name
- NCT07806877
- Testing
- Sequential Dual-Site Accelerated Theta Burst Stimulation (SD-aTBS)
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT00992407
- Testing
- Risperidone long acting injectables, Risperidone tablets
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizophreniform Disorder
Optimization of Treatment and Management of Schizophrenia in Europe
The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- OPTIMISE (NCT01248195)
- Testing
- Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment
- Where
- 26 sites in Australia, Austria and 14 more
- Volunteers
- 479 people
- Sponsor
- Rene Kahn
Schizophrenia, Schizoaffective Disorder
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive…
- Trial name
- NCT06003036
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Deepak K. Sarpal, M.D.
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation for Coordinated Specialty Care
Cognitive remediation (CR) is an evidence-based behavioral skills intervention that targets the cognitive processes underlying functioning in everyday life.
- Trial name
- NCT03930251
- Testing
- Clinic-Based Cognitive Remediation, Partial-Remote Cognitive Remediation
- Where
- 9 sites in United States
- Volunteers
- 117 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Schizoaffective Disorder, Schizophreniform Disorder
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner.
- Conditions
- Schizoaffective Disorder, Schizophreniform Disorder, Schizophrenia
- Trial name
- NCT07715253
- Testing
- Brexpiprazole, Cariprazine, [11C] PHNO
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Schizophrenia, Bipolar I Disorder
Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder
Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced…
- Trial name
- DAiP (NCT03630822)
- Testing
- Psychiatric Advanced Directive, Standard care
- Where
- France
- Volunteers
- 399 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Schizo Affective Disorder
Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With Schizophrenia
Patients affected by schizophrenia often present significant deficits in various aspects of social cognition, such as social perception, recognition of one's own and other people's emotional state and the theory of mind.
- Trial name
- SoCIAL (NCT05130853)
- Testing
- Social Skills and Neurocognitive Individualized Training (SoCIAL), Treatmment-as-usual
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- University of Campania Luigi Vanvitelli
Schizophenia Disorder, Schizoaffective Disorder
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
- Trial name
- RAMP (NCT07043803)
- Testing
- Reduction of anticholinergic medication
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple…
- Trial name
- NCT05779241
- Testing
- LYN-005, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- Lyndra Inc.
Schizophrenia, Schizoaffective Disorder
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by…
- Trial name
- NCT02069392
- Testing
- Cognitive remediation training, Nicotine polacrilex lozenge
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Tetrabenazine for Partial Responders
Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action…
- Trial name
- NCT00362804
- Testing
- Tetrabenazine
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health